Abacavir (Ziagen): Research: 2002
- Secondary Syphilis and Abacavir Hypersensitivity Reaction (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Genotypic and Virtual Phenotypic Correlates of Virologic Response to Abacavir-Based Therapy in the ZORRO Trial (ESS40009) (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir Use in HIV-Positive Pregnant Women (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Simplification of Protease Inhibitor-Based Highly Active Antiretroviral Regimens With Abacavir Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (July 10, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Genetic Test for Abavacir Reaction (Summer/Autumn 2002)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Using Abacavir to Avoid Lipid Problems (March 20, 2002)
Report from the 9th Annual Retrovirus Conference.
From Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
- HLA-B57 and TNF-Alpha Variants Associated With Hypersensitivity Reactions to Abacavir Among HIV-1-Positive Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The Presence of HLA-B*5701, -DRB1*0701, and -DQ3 Is Highly Predictive of Hypersensitivity to the HIV Reverse Transcriptase Inhibitor Abacavir (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
